Insider Trading April 28, 2026 04:04 PM

AGNC Investment Corp. CEO Executes Multi-Day Share Sale Totaling Over $2.1 Million

Peter J. Federico disposes of 193,234 shares amid strong recent earnings and a consistent dividend history.

By Avery Klein AGNC
AGNC Investment Corp. CEO Executes Multi-Day Share Sale Totaling Over $2.1 Million
AGNC

Peter J. Federico, serving as the CEO, President, and Chief Investment Officer of AGNC Investment Corp. (NASDAQ:AGNC), has completed a series of stock sales totaling approximately $2,126,604. The transactions involved the sale of 193,234 shares of common stock conducted over three distinct trading days in late April 2026. While these insider moves occur alongside robust quarterly financial performance and a long-standing dividend track record, analysis suggests the stock may currently be trading above its estimated fair value.

Key Points

  • AGNC reported Q1 2026 EPS of $0.42 and revenue of $1.05 billion, beating projections.
  • CEO Peter Federico sold 193,234 shares across three days in late April for $2.1 million.
  • The stock carries a 13% dividend yield with a 19-year history of consistency.

Executive Transaction Details

The divestment by Mr. Federico was executed in three separate tranches between April 24 and April 28, 2026. The execution prices for these shares fluctuated within a range of $10.908 to $11.079 per share.

The breakdown of the individual sales is as follows:

  • April 24: Mr. Federico sold 64,411 shares at a weighted average price of $10.908. These transactions were carried out at various points throughout the day with prices spanning from $10.835 to $11.035.
  • April 27: An additional 64,411 shares were sold at a weighted average price of $11.029, with individual transaction pricing between $11.015 and $11.05.
  • April 28: The final portion of the sale involved 64,412 shares, which reached a weighted average price of $11.079. The specific prices during this window ranged from $11.055 to $11.115.

Following these liquidations, Mr. Federico maintains a significant direct interest in the company, holding 1,927,082.869 shares of AGNC Investment Corp. common stock. This total includes 8,560 dividend equivalent restricted stock units that were derived from previously granted RSU awards since his most recent Form 4 filing. Furthermore, he holds an indirect position of 1,900 shares through an IRA.


Financial Performance and Market Context

The timing of these sales comes on the heels of a strong first quarter for 2026. AGNC Investment Corp. reported financial results that exceeded market expectations. The company posted earnings per share (EPS) of $0.42, which was higher than the anticipated $0.37. Additionally, revenue for the quarter reached $1.05 billion, outperforming the projected figure of $988.6 million.

From a historical performance perspective, AGNC stock has seen a 42% return over the past year and is currently trading at $11.08, which is near the levels seen during the recent insider sales. The company also maintains a 13% dividend yield and has a history of consistent dividend payments spanning 19 consecutive years.

Key Points and Market Impact

  • Strong Earnings Momentum: The company's ability to beat both EPS and revenue estimates for Q1 2026 suggests operational strength within the mortgage real estate investment trust (mREIT) sector.
  • Dividend Reliability: With 19 years of consecutive payments and a 13% yield, the stock remains a significant focus for income-oriented investors in the financial markets.
  • Valuation Discrepancy: Despite recent gains, analysis indicates that AGNC may be overvalued relative to its fair value, which serves as a critical context for executive selling activity.

Risks and Uncertainties

  • Valuation Risk: The assessment that the stock is currently overvalued relative to its fair value poses a risk to investors who may be purchasing at elevated price points.
  • Analyst Outlook: While recent earnings were positive, Barclays has maintained an Equalweight rating on AGNC with a price target of $10.00, as reiterated by analyst Mark DeVries, suggesting potential downside from current trading levels near $11.08.

Risks

  • Current trading prices may exceed the company's estimated fair value.
  • Barclays maintains an Equalweight rating with a $10.00 price target, below current levels.

More from Insider Trading

United Therapeutics CFO Executes $5.69 Million Stock Sale via Pre-Scheduled Trading Plan Apr 28, 2026 Belite Bio Chief Scientific Officer Executes Planned Share Sale Amid Regulatory Milestones Apr 28, 2026 Remitly Global Executive Executes Planned Stock Sale Amid Strong Financial Performance Apr 28, 2026 Valmont Industries Director Mogens C. Bay Executes $8.6 Million Share Sale Apr 28, 2026 Applied Digital Director Executes Stock Sale Amid Significant Revenue Growth and Major Lease Agreement Apr 28, 2026